Quarterly report pursuant to Section 13 or 15(d)

Licensing Arrangements (Details)

v3.19.3
Licensing Arrangements (Details) - Licensing agreements for development and commercialization
$ in Millions
1 Months Ended
Apr. 30, 2018
USD ($)
Pharmbio Korea Inc  
Licensing Arrangements  
Upfront payment $ 3.0
Withholding taxes $ 0.5
Time period for written notice to terminate license agreement 180 days
Pharmbio Korea Inc | Minimum  
Licensing Arrangements  
Time period to form a committee prior to the anticipated date of regulatory approval 6 months
Pharmbio Korea Inc | Maximum  
Licensing Arrangements  
Commercialization milestone payments $ 0.5
Royalties on product sales, percentage 20.00%
Jiangsu Nhwa Pharmaceutical Co Ltd  
Licensing Arrangements  
Upfront payment $ 2.5
Withholding taxes $ 0.3
Royalties on product sales, percentage 10.00%
Time period for written notice to terminate license agreement 180 days
Time period to form a committee prior to the anticipated date of regulatory approval 6 months
Milestone payment $ 3.0
Jiangsu Nhwa Pharmaceutical Co Ltd | Maximum  
Licensing Arrangements  
Commercialization milestone payments $ 6.0